Treatment of Uncomplicated Cystitis
For uncomplicated cystitis in an otherwise healthy adult woman, nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days is the preferred first-line treatment due to minimal resistance, low collateral damage, and efficacy comparable to other regimens.
First-Line Treatment Options
The IDSA/ESMID guidelines provide clear hierarchical recommendations for empirical treatment 1:
Primary Recommendation
- Nitrofurantoin monohydrate/macrocrystals: 100 mg twice daily for 5 days (A-I evidence)
- Minimal resistance rates
- Low propensity for collateral damage (does not promote multidrug-resistant organisms)
- Efficacy comparable to 3-day trimethoprim-sulfamethoxazole regimens
Alternative First-Line Options
Trimethoprim-sulfamethoxazole (TMP-SMX): 160/800 mg (one double-strength tablet) twice daily for 3 days 1
- Critical caveat: Only use if local E. coli resistance rates are <20% AND the patient has not used this antibiotic for UTI in the previous 3 months
- The 20% resistance threshold is based on expert opinion from clinical, in vitro, and mathematical modeling studies 1
Fosfomycin trometamol: 3 g single oral dose 1
- Minimal resistance and collateral damage
- Important limitation: Inferior efficacy compared to standard short-course regimens per FDA data 1
- Convenient single-dose administration
Pivmecillinam: 400 mg twice daily for 3-5 days 2
- Limited availability (primarily Europe; not available in North America) 1
- Minimal resistance and collateral damage
- May have inferior efficacy compared to other options
Agents to Avoid or Reserve
Fluoroquinolones (Ciprofloxacin, Levofloxacin, Ofloxacin)
Should NOT be used as first-line therapy 1
- While highly efficacious in 3-day regimens (A-I evidence)
- Significant propensity for collateral damage (promotes multidrug-resistant organisms)
- Should be reserved for more serious infections like pyelonephritis
- Increasing resistance rates globally 3, 4
Beta-Lactams
Use only when other recommended agents cannot be used 1:
- Amoxicillin-clavulanate, cefdinir, cefaclor, cefpodoxime-proxetil: 3-7 day regimens
- Generally inferior efficacy and more adverse effects compared to other UTI antimicrobials
- Cephalexin is less well studied but may be appropriate in certain settings
Never Use for Empirical Treatment
Amoxicillin or ampicillin alone: Poor efficacy and very high worldwide resistance rates 1
Clinical Decision Algorithm
Step 1: Confirm diagnosis
- Dysuria, frequency, urgency in otherwise healthy premenopausal, nonpregnant woman
- No fever, flank pain, or signs of pyelonephritis
- No urological abnormalities or significant comorbidities
Step 2: Select antibiotic based on:
- Local resistance patterns (most critical for TMP-SMX)
- Recent antibiotic exposure (avoid TMP-SMX if used in past 3 months)
- Patient allergies and tolerance
- Drug availability
- Concern for early pyelonephritis (avoid nitrofurantoin, fosfomycin, pivmecillinam if suspected)
Step 3: Default to nitrofurantoin unless contraindicated
- Achieves optimal balance of efficacy, resistance profile, and antimicrobial stewardship
Important Caveats
Diagnostic testing: Urine culture is NOT routinely needed for typical uncomplicated cystitis 2. However, obtain culture if:
- Symptoms don't resolve or recur within 2-4 weeks after treatment
- Atypical symptoms present
- Suspected pyelonephritis
- Pregnancy
Symptomatic treatment: For mild-to-moderate symptoms, some European and Australian guidelines suggest considering symptomatic therapy (e.g., ibuprofen) as an alternative to immediate antibiotics 2, 5. However, US guidelines do not currently recommend this approach 5.
Resistance considerations: The traditional first-line agent TMP-SMX has been downgraded due to rising resistance rates, particularly outside the United States 1. Always verify local resistance patterns before empirical use.
Post-treatment: Routine follow-up urinalysis or culture is NOT indicated for asymptomatic patients 2.
The 2024 EAU guidelines 2 and 2024 WikiGuidelines consensus 6 align with these IDSA/ESMID 2011 recommendations, confirming their continued validity despite being over a decade old. The emphasis on antimicrobial stewardship—minimizing collateral damage while maintaining efficacy—remains the cornerstone of modern UTI management.